Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

sibenadet

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Libraries of dibasic compounds designed around the molecular scaffold of the DA(2)/β(2) dual agonist sibenadet (Viozan™) have… Expand
  • figure 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?
2011
2011
Starting with the molecular scaffold of the DA(2)/β(2) dual agonist sibenadet (Viozan™), a number of molecular changes were… Expand
Is this relevant?
2007
2007
AIMS We sought to investigate subject specific QT interval correction factors (SSCF) determined at rest and after exercise and to… Expand
Is this relevant?
2004
2004
1. Sibenadet (Viozan), a dual dopamine D(2)/beta(2)-adrenoceptor agonist, suppresses histamine-induced tachypnoea in the dog by… Expand
Is this relevant?
2003
2003
Viozan, (Sibenadet HCl, AR-C68397AA) is a dual D2 dopamine receptor, beta2-adrenoceptor agonist that combines bronchodilator… Expand
Is this relevant?
2003
2003
Viozan (sibenadet HCl, AR-C68397AA) is a novel dual D2 dopamine receptor, beta2-adrenoceptor agonist, developed specifically to… Expand
  • figure I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2003
2003
In order to identify healthcare resource use patterns associated with chronic obstructive pulmonary disease (COPD), resource… Expand
Is this relevant?
2003
2003
The need to manage the key symptoms of chronic obstructive pulmonary disease (COPD) (breathlessness, cough and sputum) is an… Expand
Is this relevant?
2003
2003
Viozan (sibenadet HCl, AR-C68397AA) is a novel dual D2 dopamine receptor, beta2-adrenoceptor agonist that has been investigated… Expand
Is this relevant?
2003
2003
This paper describes the rationale for the development of dual dopamine D2-receptor and beta2-adrenoceptor agonists as potential… Expand
Is this relevant?